Sanei Hamid, Heshmat-Ghahdarijani Kiyan, Asadi Ali, Kermani-Alghoraishi Mohammad, Safaei Ali, Sadeghi Masoumeh
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
ARYA Atheroscler. 2023 Jul;19(4):1-10. doi: 10.48305/arya.2022.11886.2722.
The use of allopurinol has shown promising outcomes in reducing oxidative processes responsible for atherogenic-related cardiovascular events. The current study aims to assess the effects of high-dose allopurinol on the post-revascularization coronary blood flow and inflammatory biomarkers in patients with non-ST segment elevated myocardial infarction (NSTEMI).
Eighty NSTEMI patients were randomly divided into two groups: the intervention group (n=40), medicated with a high loading dose of 600 mg allopurinol before the coronary angiography, and the control group (n=40), treated with a placebo. The highly sensitive C-reactive protein (hs-CRP) was measured at baseline and within 24 hours after the cardiac interventions and compared between the case and control groups. Post percutaneous coronary intervention (PCI) Thrombolysis in Myocardial Infarction (TIMI) flow grading was also evaluated as a revascularization endpoint.
The two groups of the study were similar in terms of demographic, clinical, laboratory, and angiographic characteristics (P-value>0.050). The assessed TIMI flow was similar between the cases and the controls both prior to (P-value=0.141) and after (P-value=0.395) the coronary angioplasty. The hs-CRP (P-value=0.016) was significantly higher in the control group. Post-angiographic assessment of hs-CRP revealed an insignificant difference between the groups (P-value=0.104).
In conclusion, premedication with a high dose of allopurinol in NSTEMI patients did not affect the inflammatory biomarker or the revascularization endpoint.
别嘌醇在减少与动脉粥样硬化相关的心血管事件的氧化过程中显示出了有前景的结果。本研究旨在评估高剂量别嘌醇对非ST段抬高型心肌梗死（NSTEMI）患者血管重建术后冠状动脉血流和炎症生物标志物的影响。
80例NSTEMI患者被随机分为两组：干预组（n = 40），在冠状动脉造影前给予600 mg高负荷剂量的别嘌醇；对照组（n = 40），给予安慰剂治疗。在基线时以及心脏干预后24小时内测量高敏C反应蛋白（hs-CRP），并在病例组和对照组之间进行比较。经皮冠状动脉介入治疗（PCI）后心肌梗死溶栓（TIMI）血流分级也作为血管重建终点进行评估。
研究的两组在人口统计学、临床、实验室和血管造影特征方面相似（P值>0.050）。冠状动脉成形术前（P值=0.141）和术后（P值=0.395），病例组和对照组的TIMI血流评估相似。对照组的hs-CRP（P值=0.016）显著更高。血管造影后hs-CRP评估显示两组之间无显著差异（P值=0.104）。
总之，NSTEMI患者术前给予高剂量别嘌醇不影响炎症生物标志物或血管重建终点。
